🇺🇸 FDA
Patent

US 6083503

Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection

expired A61KA61K38/2013A61K39/35

Quick answer

US patent 6083503 (Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jun 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jul 04 2000 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K38/2013, A61K39/35, A61P, A61P37/06